about
The pseudokinase MLKL mediates necroptosis via a molecular switch mechanismIntegration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activityA mutation in the translation initiation codon of Gata-1 disrupts megakaryocyte maturation and causes thrombocytopenia.Colorectal cancer intrinsic subtypes predict chemotherapy benefit, deficient mismatch repair and epithelial-to-mesenchymal transitionIdentification of recurrent FGFR3 fusion genes in lung cancer through kinome-centred RNA sequencing.ChIP-seq analysis reveals distinct H3K27me3 profiles that correlate with transcriptional activityJarid2 regulates hematopoietic stem cell function by acting with polycomb repressive complex 2.JAFFA: High sensitivity transcriptome-focused fusion gene detection.Clonogenic mast cell progenitors and their excess numbers in chimeric BALB/c mice with inactivated GATA-1The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.Taming the dragon: genomic biomarkers to individualize the treatment of cancer.Hls5 regulated erythroid differentiation by modulating GATA-1 activity.A non-canonical function of Ezh2 preserves immune homeostasis.PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Mechanisms of Therapy Resistance in Patient-Derived Xenograft Models of BRCA1-Deficient Breast Cancer.Polycomb repressive complex 2 component Suz12 is required for hematopoietic stem cell function and lymphopoiesis.The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting.Epigenetic regulator Smchd1 functions as a tumor suppressor.Polycomb repressive complex 2 (PRC2) suppresses Eμ-myc lymphoma.BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock to Reprogramming.Opposing roles of polycomb repressive complexes in hematopoietic stem and progenitor cells.An α-E-catenin (CTNNA1) mutation in hereditary diffuse gastric cancer.Integrative modeling identifies key determinants of inhibitor sensitivity in breast cancer cell lines.MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AMLClinker: visualizing fusion genes detected in RNA-seq dataHematopoietic defects in the Ts1Cje mouse model of Down syndromeSuperFreq: Integrated mutation detection and clonal tracking in cancerAcquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaOn fitness: how do mutations shape the biology of cancer?
P50
Q27685465-4F7D23C5-B0E2-4F09-9D90-999EA5FE1A6AQ31034941-68FCD97A-A84F-4B01-9F2D-59CB7167AF6AQ33328634-3959869E-3A8B-4CDF-B8C6-E5681142B7CBQ33372611-28CBDCBE-68F4-4CE9-8003-96BB3D163900Q34522228-87839128-EE80-4EE2-9BE7-5619260CE712Q34714085-B382D5D5-F907-48E1-93C2-3F17A7FCB986Q35224324-D238AC26-B9DD-48F0-8304-402576E0E837Q35582877-842D648B-C97E-44AD-9130-0BD54975D9B4Q35654131-C8982788-6B50-4D26-ABD3-D5BB1AC6FB4DQ36276931-3DE10536-9053-4327-B09B-2905310E6CA0Q37035832-E3F131F8-E02D-4733-A6A3-C70D77275B52Q37380424-7BDFB4D7-290C-481C-9093-F8FCA3EDE2E3Q37851009-BEB64287-D90F-46C8-81E1-3C67C7F6ACF7Q38295601-3224AD46-E718-48C2-AAF3-65B17D5480A9Q38715444-B02E934E-AA73-4AF9-AA29-47B7E746D925Q39767744-A74F9FF6-C1C2-46A7-B801-2117C2297D1AQ40665907-F78DD863-3CA5-4D92-B319-8AF58087A51CQ40876632-40463994-683D-44A8-88EA-86714E44DBEAQ41542872-2EC90C1E-9049-4411-927F-1550083225ADQ46099263-C0AF49ED-2F7F-4E18-BA3D-B5D27C7FEF2BQ47687051-1F7E5AF2-5C64-4D3E-8D3A-E45BF24A47D6Q50423735-6E4CABE7-5DEA-4582-B94C-2F19AE8E3A14Q51909013-D5ABFA3F-DC3F-47CF-952F-E78805115864Q53131124-77C1A004-EF2B-4D9C-8065-AA4660C0D100Q54977815-F04F7D66-A1FE-431C-BDEE-7CB8475C1005Q57024681-13DDB494-669E-468E-BEEF-4BD185309BFFQ57073246-470E8643-50C1-4719-B185-245ADD037A3DQ62819327-D29B3DE6-5DC9-49AD-9662-25966142433FQ89695531-ABC1CB4C-67FA-4A29-875F-6CD460E4FB74Q90258038-816D3A06-8850-4C7A-8858-88B7049854FAQ92235342-B9E9AAF8-F146-4EDD-9A5D-15FD1F78E1B7
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Ian J Majewski
@ast
Ian J Majewski
@en
Ian J Majewski
@es
Ian J Majewski
@nl
type
label
Ian J Majewski
@ast
Ian J Majewski
@en
Ian J Majewski
@es
Ian J Majewski
@nl
altLabel
Majewski IJ
@en
prefLabel
Ian J Majewski
@ast
Ian J Majewski
@en
Ian J Majewski
@es
Ian J Majewski
@nl
P106
P31
P496
0000-0002-6087-635X